Claris Lifesciences’ consolidated net profit has declined by 10.70% to Rs 126.26 crore for FY11 from Rs 141.44 crore in the previous year. The company’s consolidated net sales also declined by 1.8% to Rs 738.76 crore from Rs 752.33 crore.Tts earnings per share declined to Rs 19.78 from Rs 27.34 in the last year.
The company’s board has recommended a dividend of Rs 2 per share or 20% for the year 2011.
The company has commercialized sales across 91 countries worldwide and has 1,228 product approvals out of which 207 are in the regulated market and has filed for 357 marketing authorizations under registration out of which 122 are in the regulated market.
| Company Name | CMP |
|---|---|
| Redington | 220.70 |
| Adani Enterprises | 2300.50 |
| Amrapali Industries | 17.45 |
| Rashi Peripheral | 475.55 |
| PDS | 285.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: